Alnylam Pharmaceuticals is being considered as a potential growth stock, with some outlets suggesting it may be one of the best in its class. The company's stock price and growth prospects are being evaluated, with factors such as its drug pipeline and revenue growth potential being taken into account. Some financial institutions, such as Morgan Stanley, have adjusted their price targets for the company, indicating a positive outlook.